Skip to main content

Acute Moderate-to-severe Pain

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Talphera
TalpheraCA - San Mateo
1 program
1
sufentanil sublingual tablet 30 mcgPhase 31 trial
Active Trials
NCT02662556Completed140Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Talpherasufentanil sublingual tablet 30 mcg

Clinical Trials (1)

Total enrollment: 140 patients across 1 trials

NCT02662556Talpherasufentanil sublingual tablet 30 mcg

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Start: Mar 2016Est. completion: Jul 2016140 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.